TRANSFUSION OF FRESH FROZEN PLASMA IN CRITICALLY ILL SURGICAL PATIENTS IS ASSOCIATED WITH AN INCREASED RISK OF INFECTION.

2006 ◽  
Vol 34 ◽  
pp. A77
Author(s):  
Babak Sarani ◽  
Jonathan Dunkman ◽  
Seema Sonnad ◽  
Laura Dean ◽  
Jeffrey Rohrbach ◽  
...  
2008 ◽  
Vol 36 (4) ◽  
pp. 1114-1118 ◽  
Author(s):  
Babak Sarani ◽  
W Jonathan Dunkman ◽  
Laura Dean; ◽  
Seema Sonnad ◽  
Jeffrey I. Rohrbach ◽  
...  

2007 ◽  
Vol 35 (7) ◽  
pp. 1655-1659 ◽  
Author(s):  
François Lauzier ◽  
Deborah Cook ◽  
Lauren Griffith ◽  
Julia Upton ◽  
Mark Crowther

2005 ◽  
Vol 33 (11) ◽  
pp. 2667-2671 ◽  
Author(s):  
Saqib I. Dara ◽  
Rimki Rana ◽  
Bekele Afessa ◽  
S Breanndan Moore ◽  
Ognjen Gajic

2015 ◽  
Vol 13 (6) ◽  
pp. 989-997 ◽  
Author(s):  
M. C. A. Müller ◽  
M. Straat ◽  
J. C. M. Meijers ◽  
J. H. Klinkspoor ◽  
E. de Jonge ◽  
...  

2013 ◽  
Vol 119 (4) ◽  
pp. 1050-1057 ◽  
Author(s):  
Marie Roguski ◽  
Kyle Wu ◽  
Ron I. Riesenburger ◽  
Julian K. Wu

Object A primary goal in the treatment of patients with warfarin-associated subdural hematoma (SDH) is reversal of coagulopathy with fresh-frozen plasma. Achieving the traditional target international normalized ratio (INR) of 1.3 is often difficult and may expose patients to risks of volume overload and of thromboembolic complications. This retrospective study evaluates the risk of mild elevations of INR from 1.31 to 1.69 at 24 hours after admission in patients presenting with warfarin-associated SDH. Methods Sixty-nine patients with warfarin-associated SDH and 197 patients with non–warfarin-associated SDH treated at a single institution between January 2005 and January 2012 were retrospectively identified. Charts were reviewed for patient age, history of trauma, associated injuries, neurological status at presentation, size and chronicity of SDH, associated midline shift, INR at admission and at hospital Day 1 (HD1), concomitant aspirin or Plavix use, platelet count, and medical comorbidities. Patients were stratified according to use of warfarin and by INR at HD1 (INR 0.8–1.3, 1.31–1.69, 1.7–1.99, and ≥ 2). The groups were evaluated for differences the in rate of radiographic expansion of SDH and in the rate of clinically significant SDH expansion resulting in death, unplanned procedure, and/or readmission. Results There was no difference in the rate of radiographic versus clinically significant expansion of SDH between patients not on warfarin and those on warfarin (no warfarin: 22.3% vs 20.3%, p = 0.866; warfarin: 10.7% vs 11.6%, p = 0.825), but the rate of medical complications was significantly higher in the warfarin subgroup (13.3% for patients who did not receive warfarin vs 26.1% for those who did; p = 0.023). For warfarin-associated SDH, there was no difference in the rate of radiographic versus clinically significant expansion between patients reversed to HD1 INRs of 0.8–1.3 and 1.31–1.69 (HD1 INR 0.8–1.3: 22.5% vs 20%, p = 1; HD1 INR 1.31–1.69: 15% vs 10%, p = 0.71). Conclusions Mild INR elevations of 1.31–1.69 in warfarin-associated SDH are not associated with a markedly increased risk of radiographic or clinically significant expansion of SDH. Larger prospective studies are needed to determine if subtherapeutic INR elevations at HD1 are associated with smaller increases in risk of SDH expansion.


Sign in / Sign up

Export Citation Format

Share Document